ADORKEM TECHNOLOGY began in 2002 to satisfy the demand from pharmaceutical companies for a reliable supplier of BAI (intermediates for API), Active Pharmaceutical Ingredients, custom synthesis for intermediates and molecules in clinical phase.

Adorkem Technology devotes itself to the synthesis of:

• Generic Drugs
• Intermediates
• Nucleosides and Nucleotides
• Penicillins
• Cephalosporins
• Steroids

Adorkem Technology offers:

• Contracts for R&D Services on Industrial Processes
• Development of Synthesis Methods
• Maximum Confidentiality Guaranteed Through Secrecy Agreements
• Intermediates and New Active Pharmaceutical Ingredients on a 1g to 1Kg Scale
• Micro Lab
• Pilot and Bulk Production of API

The Adorkem Technology Team possesses many years experience in the synthesis and scale-up of processes. Adorkem has gained considerable expertise in handling complex molecules through conventional and innovative multi-step synthesis, and, as a result, has become an important partner with industry-leading pharmaceutical companies.

Top of Page

AIS is a fusion of Italian high technical expertise and regulatory experience with Indian entrepreneurial skills creating an unprecedented successful joint venture in the manufacturing field of Active Pharmaceutical Ingredients (API’s) and it intermediates. AIS is composed of several companies including Gen Phar Pro Investments (GB) Limited, Alchymars S.p.A., I.C.M S.p.A and Sai Mirra Pharma Group.

AIS strength lies in the manufacture of API's and its related intermediates which are complex in synthesis, in a range from low to high-volume and medium/high value. Facilities are GMP certified as per WHO Guidelines with well drawn Quality policy and Quality Assurance Protocols manned by trained team of experts. AIS has two manufacturing facilities with four dedicated manufacturing sections specializing in synthetic API's (multipurpose), non Beta-lactam Antibiotics, Steroids/Hormones and Sterile Bulk API's Lyophilisation.

Facilities are capable of handling wide range of chemical reactions such as:

• Grignard
• Catalytic reduction
• Condensation
• Chlorination
• Bromination
• Amidation
• Reduction
• Cyclisation
• Diazotization
  

A spacious Research and Development Lab with well-equipped in-house Pilot plant has been integrated to work in coordination with AIS’s Italian R&D team. Also featured is an ultra modern and fully-equipped in-house analytical testing facility with state-of-the-art analytical instruments. Facilities possess well-designed Environmental protective measures in place with zero-discharge concept. Functioning as an extended manufacturing arm of the joint venture company, ALCHYMARS ICM SM PRIVATE LIMITED, Chennai, India is poised for a consistent growth year after year, at a rate much higher than the industry average.

Top of Page

ALCHYMARS S.p.A. was established in 1958 and has a long history in the development and manufacture of Active Pharmaceutical Ingredients (API) for human and veterinary use.

ALCHYMARS specializes in high value / low volume products and in process development from grams to hundred kilogram lots.

The manufacturing unit consists of a multi-purpose organic synthesis plant that operates under cGMP in accordance with strict regulatory requirements and in compliance with local environment regulations

Top of Page

A.M.S.A. S.p.A. belongs to the CFM Group, a private enterprise involved in chemistry and pharmaceuticals since 1949. Functioning within the group since 1953, A.M.S.A operates FDA inspected factories specializing in the production of pharmaceutical active ingredients for regulated markets. The increasing success of A.M.S.A. S.p.A. is grounded in a team of high-level chemists with long-standing experience of the pharmaceutical process, within a R&D team which has generated 7 process patents and while remaining within strict compliance with cGMP rules. The total A.M.S.A. production capacity is 56,000 litres, with stainless steel and glass lined reactors having a capacity range of 1,000 to 3,000 litres. Inspected by USA FDA and by AIFA, A.M.S.A. and its affiliates are presently providing over 20 molecules to the US market, hold 25 approved US-DMF and work for the 35% of their capacity in custom synthesis, as reliable partners with some of the most renowned pharmaceutical companies in the world. The ability to discover new paths of synthesis and in developing new molecules on behalf of customers, complete the picture of the skills which A.M.S.A. strives to place at the pharmaceutical industry’s disposal.

Top of Page

With over 45 years of existence and development, ANTIBIOTICE, located in Romania has extensive R&D and production capabilities. They have a very large fermentation capacity mainly devoted to Nystatin and are very interested in Custom projects from R&D to commercial.

Antibiotice is a cGMP facility and during July 2002, the facility was successfully inspected by the US Food and Drug Administration (FDA) with no FDA 483 form issued.

In addition, they have several large manufacturing facilities for dosage forms including oral, topical, injectable and suppository production which is supported by a large local sales force detailing Ethical and Generic products.

Top of Page

APOTEX PHARMACHEM has emerged as a leader in the development and manufacture of active pharmaceutical ingredients for the global pharmaceutical community.

They are located in the city of Brantford, Ontario, Canada and are proud of their state-of-the-art facility. Included in the most recent expansion has been an additional 20,000 square feet of R&D laboratory space and state of the art equipment, to double their Research & Development capabilities.

Over 20 commercial products, more than 30 commercially valuable patents granted and the ability to handle 25 discrete projects at any one time testify to their in-house specialties.

The main mission of APOTEX PHARMACHEM in-house cGMP Production Team is the transfer of technology from laboratory to plant and to contract manufacturers with scale-up, with economical and ecological considerations being paramount.

Top of Page

ARCHIMICA–Archimica is one of the world's leading global fine chemicals businesses focused solely on commercialization solutions for the pharmaceutical industry delivering a global cGMP manufacturing capability with pharmaceutical services, R&D and technology development assets to create a world-scale outsourcing partner for leading pharmaceutical companies. Based in Frankfurt, Germany, Archimica has operations in the United States, the United Kingdom, France and Italy, as well as a technology center in Germany.  Archimica’s offerings to the industry include regulatory starting materials, high-tech building blocks, cGMP intermediates and active pharmaceutical ingredients.

Top of Page

BILIM PHARMACEUTICALS –Employing 1761 people and reaching an annual turnover of over $300 million, Bilim has become the 3rd largest company in Turkey among national and multinational manufacturers.  Bilim offers global partnership opportunities ranging from Contract Manufacturing, Distributorship/Agencies, In-Licensing agreements for its potential partners. Bilim organizes the production supply chain from two manufacturing facilities.  Their Cerkezkoy Plant is the 3rd largest B-Lactamic plant in Europe.  Their new Gebze Plant (an investment of over 70m²) is currently under construction in Istanbul according to FDA guidelines.  This plant will be operating through the last quarter of 2007 with an annual capacity of 125m pack/year.

Top of Page

BIOINDUSTRIA L.I.M. is able to offer both a large range of finished active ingredients in bulk for the pharmaceutical industry and the development of specialized custom synthesis for "highly demanding" customers.

The activities of the company are:

• Production of large volume I.V. Solutions
• Production of Generics
• Manufacturing and marketing of bulk active ingredients for the pharmaceutical industry
• Manufacturing and marketing of flavours and fragrances

The manufacturing of API is carried out at their recently constructed plant in Fresonara near Novi Ligure.

Established with the intention of supporting its own pharmaceutical activities, the Fresonara plant has in a short time, improved the efficiency of the overall organization by increasing its production capacity.

All products are supported by DMF's that are filed in house by BIOINDUSTRIA L.I.M. staff.

BIOINDUSTRIA'S Quality System has been recognized by the FDA (the last approval on July 2001), following an inspection of the plant and their analytical laboratories; as well as many successful audits by major Italian and foreign pharmaceutical companies and their respective countries’ Health Authority.

BIOINDUSTRIA L.I.M. is always accessible to customer’s audits.

Top of Page

CF PHARMA Having 165 m3 overall reactor capacity (ranging 0.1 to 16 m3 of reactor size) it is ideally suited for small- to medium volume of API or intermediate production.

CF Pharma is specialized in extraordinary or special technologies requiring the comprehensive and up-to-date chemical and technological knowledge of its staff. Besides the custom syntheses which are based on either the partners' or on its own know-how, CF Pharma is also involved in the development of manufacturing technologies of APIs.

The quality control department is capable to provide all the necessary background for batch control as well as stability studies.

The company possesses a class C clean room that allows CF PHARMA to manufacture APIs for intravenous injection.

Top of Page

Hunan Kangyan is one of the three subsidiaries of ChinaSun Group. The Hunan Kangyuan company specializes in pharmaceutical manufacturing and is located on the heart of HuNan province, Changsha city and is a leading enterprise in the pharmaceutical sector that is comprised of three distinct organizations; manufacturing equipment (Pharmaceutical Machine Co. Ltd.), manufacturing pharmaceuticals (KangYuan), and pharmaceutical packaging (Novel).

ChinaSun Machinery not only builds simple operation, high efficiency pharmaceutical equipment for pharmaceutical procession but they also offer production lines that include Non-PVC membrane I.V. multi-chamber bags, plastic bottle infusion, plastic bottle ampoule, glass bottle high-speed infusion, injectables, compact ampoule line, oral liquid, antibiotics, opthalmics, bottle filled syrup and suppository manufacturing product lines.

ChinaSun Novel specializes in the research, development and manufacturing of a number of packaging products including; multiple layer non-PVC membrane, plastic containers for intravenous fluid using PPC stoppers and caps, connectors, suppository packages and plastic bottles. ChinaSun currently owns more than 150 patents and is committed to continuous development. The key to ChinaSun's success is their efficient management system, sophisticated technology and excellent production plants. Their mission statement is "Providing excellent products and services for the consumer."

Top of Page

COSMA S.p.A. was founded in 1977 and is located in Ciserano (Bergamo). Its integrated manufacturing facility is FDA approved, and has the flexibility to widen its product capacity and to harmonize GMP philosophy.

COSMA is specialized in the organic synthesis of Active Pharmaceutical Ingredients (API) and their strategy is to dedicate a portion of their production capacity to custom manufacturing with selected pharmaceutical companies.

The synergetic work of the R&D departments gives Cosma more capability to study and develop new routes of synthesis in a short time, with the submission of new patents. Their strategy is to invest in the growth of their R&D department capability and in new technologies.

COSMA is a strong believer in ensuring friendliness to the environment. They own an important partnership in a municipal wastewater treatment plant and an additional partnership in a large incineration plant for chemical waste. An innovative system for biological wastewater treatment has been in place since the end of 1997.

Top of Page

DK Pharma is a dynamic entity, manufacturing various Specialty, Fine Chemicals and Intermediates since 1980; meeting the needs of national as well as international customers with continuous development.

Their state-of-the-art manufacturing plant, equipped with modern production facilities is located 40 kilometers from Mumbai and is now venturing into the manufacturing of Active Pharma Ingredients. This WHO cGMP-compliant facility is supported with dedicated quality control and research and development departments which are responsible for continuous innovations in products and processes.  DKpharma’s dedicated team of analytical chemists ensures product conformity to the highest analytical standards.

Top of Page

DELPHARM is a French pharmaceutical firm whose main business activity is the shaping of medicines for human and veterinarian use. Delpharm has 4 manufacturing sites and specializes in manufacturing and packaging drugs for major pharmaceutical companies. Delpharm offers complete industrial manufacturing, packaging, and control of drugs including liquid forms (sterile injectables), solid forms (tablets, capsules) and semi solid forms (creams, ointments). In addition to manufacturing conventional products, Delpharm also has the capability for manufacturing high potent hormones and oncologicals. Delpharm is ranked 3rd among French Contract Manufacturing Organisations. Their target market is Europe and they are currently gearing their efforts towards the North American market.

Top of Page

DERIVADOS QUIMICOS, S.A.. was founded in January 1987, in Murcia, Spain, and in 1990, the company started manufacturing and marketing APIs and advanced intermediates for APIs.  The company has specialized in the manufacture of chemicals under GMP conditions and according to our clients' demands (custom synthesis) including: Acylation, Alkylation, Amidation, Diazotation, Cannizzaro, Carboxylation, Catalytic reduction, Chloromethylation, Chlorosulfonation, Condensation, Cyanation, Diels-Alder, Epoxidation, Esterification, Etherification, Friedel-Crafts, Grignard, Halogenation, Hydrogenation, Methoxylation, Methylation, Neutralisation, Nitration, Oxidation, Reduction, Saponification. Derivados Químicos' facilities and services enable them to perform over 30 different chemical reactions, with a total production capacity of 500 MT per year. Additionally, Derivados Químicos uses special reagents such as PCl3, POCl3, SO4(CH3), SOCl2, BuLi, NaH, NaBH4, LiAIH4, etc. The company currently holds the ISO-9001:2000 certification (certification body: AENOR), ISO-14000 certification, and has successfully been US FDA inspected. The trend of Derivados Químicos, S.A. to date has been of constant growth and improvement, exhibiting great flexibility in the variety of products and increased production capacity.

Top of Page

The EUTICALS Group consists of 5 companies concerned with the development and production of intermediates and APIs with different production technologies.

All the companies belonging to EUTICALS group run their activities in accordance with current GMP regulations requested by competent authorities, and have been FDA inspected.

EUTICALS began its operations in 1984, with the acquisition of the chemical division of Istituto Chemioterapico Italiano S.p.A. a chemical-pharmaceutical company founded in 1946 in the present location of San Grato (Lodi). The facility has a surface of 23,000 sqm. It has been recently renovated and its reactors and vessels total 200,000 liters. EUTICALS is a qualified supplier of bulk pharmaceuticals as well as active ingredients for the pharmaceutical and nutritional industries. It produces drugs, which are used in the field of anti-ulcers, treatment of central nervous system illnesses, infections of the respiratory tract and other disorders. Pharmaceutical intermediates with its own and / or custom technologies are also manufactured. Currently EUTICALS produces approximately 500 tonnes / year of pharmaceuticals, active ingredients, nutriceutical and intermediates. Euticals meets cGMP and G.L.P standards as well as environmental protection requirements (according to EC regulations). The Company recently underwent a successful FDA inspection.

AMBROSIA, thanks to its research and pilot development structure and capability, is able to produce the small quantities necessary for the pharmacological development and registration of a new molecule; at the same time AMBROSIA can work out an industrial production process to be transferred to the other companies of the group (Euticals or Prochisa), as to satisfy customer needs when launching the product in the market.

During years of increasing activity, PRO.BIO.SINT. has instead pursued the production of ribonucleic acid and deoxyribonucleic acid derivatives. Thanks to its experience PBS can produce key intermediates and new sophisticated “antisense” molecules. The technologies available from PBS, ranging from synthesis to enzymatic and fermentative processes, are new and advanced.

Thanks to their volumetric capacity, EUTICALS and PROCHISA can evaluate and satisfy exclusive API production proposals with different and sophisticated process technologies.

Top of Page

EVERLIGHT, founded in 1972, is an international high-tech chemical manufacturer, headquartered in Taiwan.  Everlight achieves sustainable growth by balancing economic, social and environmental responsibilities and workers’ safety.  Since 1992, Everlight’s pharmaceutical division started its R&D development in prostaglandins and has successfully commercialized several active pharmaceutical ingredients with DMF submission to the U.S. FDA.  In addition, Everlight’s specialty in cardiovascular medicine also plays a significant role in assisting their clients to secure their global market share in Felodipine products.  Everlight’s grows together with their clients through mutual cooperation.  In addition to this, Everlight is also closely involved in Chiral intermediates and synthetic organic chemistry.

Top of Page

Top of Page

FERMIC, S.A. DE C.V., started production in 1968 in its present location in Mexico City, with a fermentation capacity of about 100,000 liters.

Over the years the initial capacity has increased ten fold, making Fermic one of the largest antibiotic fermentation plants in Latin America and by the end of 2002 this capacity will have grown further still to a level of 1.4 million liters.

The complete plant is in s/s 304 & 316 and is "MULTIPURPOSE" which means it can produce a variety of products by fermentation for oral and sterile injectable grade.

The plant also includes important multipurpose facilities for the synthesis of antibiotics and other products.

The plant is FDA / USA approved since 1971 and the last inspection was in May, 1996.

PILOT PLANT:
5 x 500 liters fermentors plus related prefermentors.

FERMENTATION COMMERCIAL CAPACITY:
900,000 lts. plus related prefermentors.

RECOVERY:
3 recovery systems:

1.By precipitation
2.By resins
3.By solvents

FERMIC has an important R&D unit for strain development and improvement and for new biological and chemical products by synthesis.

FERMIC is interested in considering customers’ manufacturing of biotechnological products.

Top of Page

FORMOSA LABORATORIES, Inc. was established in 1995 as a contract research laboratory specializing in chemical process development, analytical service, and small scale production.

Since inception, their business has been expanded to include the commercial production of API’s /advanced intermediates and other high value-added specialty chemicals.

With their strong experience in process validation, scale-up capability, and flexible cGMP manufacturing facilities (50-1,000 L), FORMOSA is aiming at becoming a major player in custom synthesis. FORMOSA commits itself to the manufacture of all its pharmaceutical products in accordance with cGMP (ICH Q7A) and by the methods described in specific drug master files . They have been inspected / audited by local authorities, local and foreign companies and have now been successfully inspected by the US FDA and are ISO 9001 certified.

Top of Page

GENETIC, S.p.A. – Genetic’s prime business strategy is to develop generic drugs and offer complete dossiers for finished dosage forms.  Genetic S.p.A. was born with the objective to develop and to manufacture unit dose in Polyethylene or Polypropylene and pressurized metered dose inhaler (p MDI) for anti-asthmatic products, ophthalmological drugs, nasal products, OTRL, solutions and suspensions.  Today, Genetic’s new factory is ready with a total area of 13,000 m², comprising 4,500 m² of cGMP-designed production facilities, with a daily capacity of 5000,000 unit doses.  In 2008, Genetic will be working towards successful FDA approval.  In addition to these physical products, Genetic also actively markets their research and development skills, and expertise with regard to sterile manufacturing and the registration of active pharmaceutical ingredients (steroids).

Top of Page

GLOCHEM– Established in 1996, Glochem is a manufacturer & marketer of APIs, drug intermediates, OPC/OLED and fine chemicals.  They also are actively involved in custom synthesis as well as contract manufacturing.  Glochem is particularly proud of their low senior management turnover, resulting in efficiencies that enable easier and quicker development.  Glochem recently successfully participated in a U.S. FDA inspection.

Top of Page

HAINAN HAILING PHARMACEUTICAL CO. LTD., is a private-owned comprehensive enterprise engaged in R&D, Manufacturing and marketing of API and formulated drugs.

With major equipments imported from Germany, the United States, Japan and Sweden, Hailing Pharm’s highly automated production lines manufacture a wide range of medicines as powder for injection, lyophilized powder for injection, small-volume water injection, capsules, tablets and suspension and all of them have gained national Certificate of Good Manufacturing Practices.

Hailing Pharm also builds up cooperative relationship with pharmaceutical industries from Japan and Korea. In 1993, Hailing Pharm and Shionogi cooperated to manufacture the patent medicine Shiomarin and in 1996, Hailing Pharm and Hanmi cooperated to produce the patent medicine Tazime.These two products have now become its leading products.

Top of Page

Top of Page

Established in 1987, JIWA BIO-PHARM HOLDINGS LTD. began as an agent for a number of European pharmaceutical companies. It was there they developed their own sales network and product development teams and gained regulatory affairs experience. This became their core strength and competitive advantage as they demonstrated a high success rate of product registrations and shortened production lead times when launching new products.

In 1993, JIWA began developing and manufacturing a wide range of generic pharmaceutical products, launched in the European market with proven results. These products were created in their own manufacturing plant located at Yunnan - known as a center of excellence for the Chinese pharmaceutical industry and the core for major government development of China’s Western region. JIWA has received a number of awards in recent years recognizing their achievements in management, product development, technology and quality.

JIWA’s product offering includes a full range of antibiotics, gastro-intestinal, rheumatology and orthopaedics, and the production of over the counter (OTC) drugs, health care products, as well as their own branded products. Throughout the years, they have gained insight in the industry and developed specialties in the anti-infectious, gastro-intestinal, and musculo-skeletal therapeutic categories. In recent years, they have concentrated on the development of antidepressant, psychiatric disorder, and cerebro-cardiovascular drugs.

A 2004 business expansion resulted in the building of a new plant at the Kunming National Hi-technology Industry Development Zone. This new complex has a gross floor area of approximately 38,000 sq. meters and 13 GMP production lines for finished dosage forms and APIs.

In 2005, JIWA expanded into API manufacturing and established Jiangsu Jiwa Rintech Pharmaceutical Co. Ltd (JJRP). This facility is located in the Jiangyin municipal of the Jiangsu province, long a leading area for chemical synthesis and pharmaceutical industry in the People’s Republic of China. The company endeavours to develop into a major international API manufacturer, producing sophisticated APIs for regulated markets, including the United States and European Union. Within the first phase, a two-production complex for oral APIs and sterile cephalosporin bulk was set up, with total area of 43,900 square meters and an investment of 95M (RMB). This facility produces a number of products including Citalopram, Risperidone, Cefipime and Cefpirome, some with DMFs already submitted to the FDA. The company has state-of-the-art production technologies, with exceptional emphasis placed on safety, health and the environment.

Looking ahead, JIWA will continue to strengthen their business in trading and developing drugs with existing molecular formulae within their core therapeutic categories, as well as cultivate their expertise in the development of their patent products and bulk materials for export into the international market

Top of Page

LABOCHIM is the manufacturing unit of INFA Group, with 50 years experience in the marketing and sales of API's throughout the world.  They maintain offices in throughout the world; in Italy , France , Germany and the U.S.

Labochim is a modern API production unit, with a 170,000 liter production capacity. This facility continues to be successfully inspected by FDA since the late 70’s, and represents the strategic asset of the INFA Group, an entity engaged for over 50 years in the worldwide marketing and sales of API’s.

Top of Page

LAFRANCOL manufactures and distributes high quality pharmaceutical products, (Ethical, Generic and OTC) as well as nutraceuticals, nutritional supplements and functional foods for Colombian and international markets.  Lafrancol’s highly qualified, certified employees and facilities have shown a dedication to the preservation of the natural environment as well as the resources utilized in the manufacturing processes.

Top of Page

LISAPHARMA, founded in 1925, focuses their efforts on the manufacturing and marketing of specialty pharmaceuticals.  They have a prosperous business arrangement where they work with local universities to offer new and exciting finished dosages technologies available for license.  LisaPharma offers cutting edge technologies to companies in the United States, Europe and around the world.  This includes patented Patch-non-Patch systems, DOME matrix in oral drug delivery, Chimerical Agglomerates for nasal delivery and several others.

Top of Page

NCPC Group Corp., located in Shijiazhuang, P.R.China, is state-owned and one of the largest pharmaceutical enterprises in China. It was established in 1953. With the development of more than half a century, it has grown up to a comprehensive pharmaceutical group with the capacity to produce over 460 varieties of bulk materials and finished products and even a conglomerate of more than 20 subsidiaries in manufacturing and trading of pharmaceuticals as well as vitamins, bio-technology products, pesticide and animal drugs.

NCPC is currently the second largest penicillin producer in the world and the Chinese largest producer on penicillin, Amoxicillin, Streptomycin, Cefradine, 6-APA and 7-ADCA.

Since 1984, NCPC has initiated modern biotech research and formed the generically engineered drug development system involving new products R&D, pilot scale and commercial scale production. At present G-CSF, GM-CSF, EPO and generically engineered hepatitis B vaccine are on market.

All the processes in the production comply with the current GMP. Through 20 years of practice of TQM and unremitting efforts in quality improvement, an efficient quality assurance system has been established to guarantee the best product quality. In 2000, North China Pharmaceutical Co., Ltd., a flagship subsidiary of NCPC, became an ISO9001 certified pharmaceutical producer.

Top of Page

Orit Laboratories specializes in generic pharmaceutical product development.  They are focused on the analytical and formulation development of solid oral dosage forms.  Orit’s 9000 square foot facility, located in West Caldwell, NJ is capable of pilot scale production and their analytical laboratory operates under cGMP.  They aim to be a premier product development company forming alliances with pharmaceutical manufacturers and marketers. Novel oral drug delivery, specialty/niche products, NDA 505(b)(2), patent challenges and brand life-cycle extensions as well as technology transfers are some of the business activities that Orit applies their expertise to.

Top of Page

POLPHARMA S.A. is located in Starogard, Gdansk, Poland. The Company was founded in 1935 and is the leading pharmaceutical company in Poland and one of the top pharmaceutical companies in Central/Eastern Europe.

POLPHARMA manufactures a wide range of active pharmaceutical ingredients (APIs) and API intermediates. The Company operates under cGMP rules (current Good Manufacturing Practice), and has been FDA inspected.

Production capabilities range from laboratory scale, to pilot plant, to full-scale production of several hundred metric tons, depending upon the chemistry involved. The Company is also continually looking at developing new and interesting API’s.

POLPHARMA currently has 11 APIs filed with the U.S. Food and Drug Administration. The Company has been selling its APIs in the United States for more than 10 years, and is looking forward to increasing its presence in this market.

Top of Page

Ragactives is a Spanish fine chemical company dedicated to the development and manufacture of non-steroidal APIs. Ragactives is a quality and market driven organization.  In March 2007, Ragactives chemical plant was audited and approved by the FDA.  Ragactives has aligned their management systems and decision-making processes with their goal of meeting customer needs within the shortest period of time.  In addition to APIs, Ragactives is involved in chemical synthesis/analysis as well as synthetic organic chemistry.

Top of Page

SIFAVITOR S.p.A. has produced fine chemicals and their intermediates for the pharmaceutical industry since 1966. Thanks to the outstanding versatility of the equipment and the vast experience of its highly skilled personnel, the company’s output, consisting of small/medium size batches, comprises a large range of active principles.

In the course of a year, the company produces over 40 chemical substances. Facilities meet GMP’s requirements and US Code of FDA plants, and is regularly inspected and approved.

Their specific technology consists of high-pressure reactions, such as condensation and catalytic reductions, which are made possible by means of autoclaves operating at pressures of up to 100 Atm.

The plant also has 25 fully equipped glass-lined and stainless-steel reactors with blanketed centrifuges, some dedicated to specific reactions (i.e. Grignard or Alkylation). A specially equipped distiller is set to work under vacuum – up to 250 degrees Celcius.

The manufacturing unit consists of vacuum dryers, vibrating sieves and a dedicated section with a mill and a micronizer.

Top of Page

SIGNA is an Active Pharmaceutical Ingredients company located in Toluca, Estado de Mexico, 40 miles west of Mexico City.

SIGNA has positioned themselves among the most important API manufacturers in Latin America with products that exceed USP and BP market requirements and standards. The facility is FDA approved and manufactures high value products such as AZT (AIDS treatment).

Every effort at SIGNA seeks compliance with cGMP’s and local / international regulatory agencies rules. It validates its processes in the plant and trains all personnel for cGMP’s. Quality Control and Quality Assurance are vital for SIGNA as they ensure that their API’s are manufactured meeting the highest quality standards.

The manufacturing area is divided into six (6) production plants covering 139,895 square feet with modern and secure facilities which provides Signa with the flexibility required to produce its variety of products.

TITAN LABORATORIES is a specialty pharmaceutical company engaged in developing and manufacturing Sustained and Modified Release Pellets using innovative drug delivery technologies. Utilizing some of the best and latest processing machinery, such as the Fluid Bed Processor which features an inherent built-in rotary unit coupled with top and bottom Spray arrangement. This is essential to achieve uniformity and efficiency in the layering and coating process to ensure consistent release characteristics. Extruder & Spheronizer equipment is also available to allow effective pelletizing selectivity tailored to dose requirements.

Titan’s specialized product development needs are well serviced by In-house R&D facilities comprising of Formulation and Analytical competencies. The CGMP-led manufacturing facility is approved by Indian Drug Authorities.  Titan’s staff and facilities are in a state of preparedness for impending customer-triggered inspections from foreign clients. These activities are ably supported by Titan’s Q.A. & Regulatory departments, who are geared towards country, as well as customer specific needs.

Top of Page

TONIRA is committed to customers all over the world for the timely supply of High Quality Pharmacopoeial Bulk Active Ingredients. This has been achieved over years of hard work, innovation and improvement. Tonira’s products are exported to over 40 countries.

Tonira has a two manufacturing sites.The site located at Ankleshwar (Gujarat) has WHO GMP approval and is certified ISO 9001:2000 by BVQI. The facility at vadodara (Gujarat) has been recently commissioned in January 2005 and is designed to meet USFDA standards for cGMP.

WAYPHARM prides itself in being an outsourcing partner in Oncology within the Pharmaceutical, Biotechnology, and Drug Delivery System Industries.  Waypharm dedicates all of their resources to pharmaceutical solutions; to developing new products and therapies; as well as manufacturing cytotoxics. 

Waypharm’s production facility is in compliance with latest regulatory requirements as well as in accordance to industry state-of-the-art practices.  There they can produce testing to industrial-sized batches and clinical batches with maximum flexibility and quality. Waypharm has a mission of Commitment to Excellence. Our vision can be summarized as Personnel Excellence, Training Excellence, Product Excellence and Service Excellence. Waypharm is dedicated to solutions that provide real results to real issues.

Top of Page

ZaCh System, established in 2007 and headquartered in Lonigo (Vicenza), is the fine chemicals company of Zambon Company (est. 1906).  This relationship benefits from the solidity and synergies of a large multinational group with the focused intent of a dedicated fine chemicals company. ZaCh System is involved in advanced intermediates for custom synthesis. They are also engaged in R&D and manufacturing as well as the marketing of bulk active ingredients and APIs for the generic market.  Supported by over one hundred years of experience, this new enterprise, ZaCh System, combines industry-leading quality with tailored process support to ensure clients meet and exceed their objectives.

Top of Page